🔎 Trials Near Me

Gara Jalqabaatti › Kansarii Ovarii › Missouri › Kansas City

Qorannoo klinikaalii Kansarii Ovarii Kansas City, MO keessatti

Qorannoo 11 Kansarii Ovarii f Kansas City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

The Vanguard Study: Testing a New Way to Screen for Cancer

Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
  • Saint Luke's Hospital of Kansas City, Kansas City
Umuriin 45 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06995898

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • HCA Midwest Kansas City, MidAmerica Division, Inc., Kansas City
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07213804

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • The University of Kansas Cancer Center, Westwood · Miili 5 fagaatti
Umuriin 18 fi ol · Dubartoota · Haaromfame 14-Ful-2026 · NCT06787612

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Namoota walitti qabaa jira
  • University of Kansas Hospital-Westwood Cancer Center, Westwood · Miili 5 fagaatti
Umuriin 35 hanga 50 · Dubartoota · Haaromfame 07-Hag-2026 · NCT04251052

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Namoota walitti qabaa jiraSadarkaa 1/2
  • University of Kansas Medical Center (KUMC), Westwood · Miili 5 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Namoota walitti qabaa jiraSadarkaa 2
  • 334, Kansas City
Umuriin 18 fi ol · Dubartoota · Haaromfame 16-Ado-2026 · NCT06906341

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Saint Luke's Cancer Institute, Kansas City
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT05768139

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • The University of Kansas Cancer Center - Westwood, Westwood · Miili 5 fagaatti
  • University of Kansas Cancer Center, Westwood · Miili 5 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT04389632

Integrated Cancer Repository for Cancer Research

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
  • Saint Luke's Cancer Institute, East, Kansas City
  • Saint Luke's Cancer Institute, Kansas City
  • Saint Luke's Cancer Institute, Kansas City North, Kansas City
  • fi 1 dabalataa
Umuriin 19 hanga 110 · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT02012699

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Cancer Center North, Kansas City
  • University of Kansas Cancer Center Westwood, Westwood · Miili 5 fagaatti
  • fi 1 dabalataa
Umuriin 18 fi ol · Dubartoota · Haaromfame 16-Elb-2026 · NCT05659381

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Massive Bio SYNERGY-AI site, Kansas City
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774

Qorannoo Kansarii Ovarii magaalota biroo keessatti

Qorannoo biroo Kansas City keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.